STRATA Skin Sciences, Inc. — fact timeline

STRATA Skin Sciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 22, 2025, Strata Skin Sciences, Inc. (the “Company”) received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). On September 19, 2025, the Company submitted a plan to Nasdaq to regain compliance”

STRATA Skin Sciences, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 22, 2025, Strata Skin Sciences, Inc. (the “Company”) received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). On September 19, 2025, the Company submitted a plan to Nasdaq to regain compliance”

STRATA Skin Sciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 19, 2025, Strata Skin Sciences, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Company reported stockholders’ equity”

STRATA Skin Sciences, Inc. engaged CBIZ CPAs P.C. as its auditor.

“On April 23, 2025, upon Marcum’s resignation as auditors of the Company and with the approval of the Company’s Audit Committee, CBIZ CPAs P.C. was engaged as the Company’s independent registered public accounting firm for the year ending December 31, 2025.”

Marcum LLP resigned as auditor of STRATA Skin Sciences, Inc..

“On April 23, 2025, Strata Skin Sciences, Inc. (the “Company”) was notified by Marcum LLP (“Marcum”) that Marcum resigned as the independent registered accounting firm of the Company.”

John Gillings was appointed as principal financial officer and principal accounting officer at STRATA Skin Sciences, Inc..

“On November 13, 2024, Strata Skin Sciences, Inc. (the “Company”) designated its Vice President Finance, John Gillings, as its principal financial officer and principal accounting officer.”

STRATA Skin Sciences, Inc. reported the first fiscal quarter ended March 31, 2024 results: revenue $6.8 million, net income Net loss of $3.4 million, EPS net loss of $0.10 per basic and diluted common share.

“announces its financial results for the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights • Revenue in the first quarter of 2024 was $6.8 million (-11% YOY) vs. $7.6 million in the first quarter of 2023 o Global net recurring revenue in the first quarter of 2024 was $4.7 million (-10% YOY) vs. $5.2 million in the first”

STRATA Skin Sciences, Inc. entered into Second Amended and Restated Fee Letter Agreement with MidCap Financial Trust valued at Fee letter agreement setting forth origination fees and exit fees related to the MidCap Credit Agree (effective 2024-02-20).

“On February 20, 2024, STRATA Skin Sciences, Inc. (the “Company”) entered into (a) the Amendment No. 4 to Credit and Security Agreement (the “Amendment”) among MidCap Financial Trust (“MidCap”), as administrative agent, and the lenders identified therein, which amended the Credit and Security Agreement, dated as of September 30, 2021, as amended January 10, 2022, September 6, 2022 and June 30, 2023 (as amended by the Amendment, the “MidCap Credit Agreement”), and (b) a second amended and restated letter agreement (the “Second Amended and Restated Fee Letter Agreement”) with MidCap, as agent.”

STRATA Skin Sciences, Inc. entered into Amendment No. 4 to Credit and Security Agreement with MidCap Financial Trust valued at Amendment to credit agreement revising minimum net revenue financial covenants to $29.0M, $29.25M, $ (effective 2024-02-20).

“On February 20, 2024, STRATA Skin Sciences, Inc. (the “Company”) entered into (a) the Amendment No. 4 to Credit and Security Agreement (the “Amendment”) among MidCap Financial Trust (“MidCap”), as administrative agent, and the lenders identified therein, which amended the Credit and Security Agreement, dated as of September 30, 2021, as amended January 10, 2022, September 6, 2022 and June 30, 2023 (as amended by the Amendment, the “MidCap Credit Agreement”), and (b) a second amended and restated letter agreement (the “Second Amended and Restated Fee Letter Agreement”) with MidCap, as agent.”

STRATA Skin Sciences, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“December 27, 2023, the Company received further notification from NASDAQ that the Company had been granted a 180 day extension to June 24, 2024 to regain compliance with the minimum bid price requirement. The Company will regain compliance if the closing bid price of its common stock is $1.00 per share or higher for a minimum period of ten consecutive business days during this compliance period, as confirmed by written notification from NASDAQ. If the Company does not achieve compliance by June 24, 2024, the Company may file an appeal to Nasdaq’s Hearing Panel with a plan to resolve the bid”

STRATA Skin Sciences, Inc. reported the third fiscal quarter ended September 30, 2023 results: revenue $8.9 million, net income Net loss for the third quarter of 2023 was $1.1 million, or a loss of $0.03 per basic and diluted common share, EPS $0.03 per basic and diluted common share.

“conditions, today announced financial results for the third quarter ended September 30, 2023. Third Quarter 2023 and Recent Business Highlights: ● Total Revenues were $8.9 million compared to $9.4 million for the third quarter of 2022, a total decrease of 6.0%. ● Non-GAAP EBITDA improved to $1.0 million compared to $0.6 million for the third quarter of”

Shmuel Gov changed role as Chief Operating Officer at STRATA Skin Sciences, Inc..

“On November 14, 2023 the Board of Directors of Strata Skin Sciences, Inc. (the “Company”) approved the promotion of Shmuel Gov to the position of Chief Operating Officer.”

STRATA Skin Sciences, Inc. shareholders approved Advisory vote on the frequency of future advisory votes to approve compensation of named executive officers at the 2023-10-26 meeting.

“The advisory vote on the frequency of future advisory votes to approve the compensation of the Company’s named executive officers was approved. One Year Two Years Three Years Abstain 11,807,110 55,248 13,612,361 14,886”

STRATA Skin Sciences, Inc. shareholders approved Advisory vote to approve compensation of the named executive officers at the 2023-10-26 meeting.

“The advisory vote to approve the compensation of the Company’s named executive officers was approved. Votes For Votes Against Abstain Broker Non-Vote 24,094,572 1,372,175 22,842 4,225,530”

STRATA Skin Sciences, Inc. shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split of common stock at a ratio not less than 1-for-5 and no greater than 1-for-25 at the 2023-10-26 meeting.

“The amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of its common stock at a reverse stock split ratio not less than 1-for-5, and no greater than 1-for-25 with the exact split ratio, it approved and effected at all, to be set within that range at the discretion of the Board and publicly announced by the Company within 6 months after stockholder approval at the Annual Meeting without further approval or authorization of the Company’s Stockholders was approved. Votes For Votes Against Abstain Broker Non-Vote 29,015,257 643,214 56,652 0”

STRATA Skin Sciences, Inc. shareholders approved Ratification of the selection of Marcum, LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-10-26 meeting.

“Ratification of the selection by the Audit Committee or the Board of Directors of Marcum, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023, was approved. Votes For Votes Against Abstain Broker Non-Vote 29,594,033 104,833 16,269 0”

STRATA Skin Sciences, Inc. shareholders approved Election of the five director nominees named in the proxy statement at the 2023-10-26 meeting.

“each of the director’s nominees to the Company’s board of directors was elected: Nominees Votes For Votes Withheld Broker Non-Vote Uri Geiger 24,964,683 524,910 4,225,530 Irit Yaniv 24,962,618 526,987 4,225,530 Wayne Cafran 25,157,665 331,940 4,225,530 Shmuel Rubinstein 24,969,443 520,150 4,225,530 Robert Moccia 23,978264 1,511,341 4,225,530”

Dolev Rafaeli was appointed as Vice-Chairman of the Board, President and Chief Executive Officer at STRATA Skin Sciences, Inc..

“the Company appointed Dr. Dolev Rafaeli, PhD, (“Rafaeli”), as its Vice-Chairman of the Board, President and Chief Executive Officer.”

Robert Moccia resigned as Member of the Board of Directors at STRATA Skin Sciences, Inc..

“Moccia resigned as the Company’s Chief Executive Officer and President and as a member of the Company’s board of directors.”

Robert Moccia resigned as Chief Executive Officer and President at STRATA Skin Sciences, Inc..

“Moccia resigned as the Company’s Chief Executive Officer and President and as a member of the Company’s board of directors.”

STRATA Skin Sciences, Inc. reported second quarter ended June 30, 2023 results: revenue $8.3 million, net income $3.1 million, or a loss of $0.09 per basic and diluted common share, EPS $0.09 loss per basic and diluted common share. Guidance lowered.

“today announced financial results for the second quarter ended June 30, 2023. Second Quarter 2023 and Recent Business Highlights: ● Revenues in the second quarter of 2023 were $8.3 million, compared to $9.1 million for the second quarter of 2022. ● Secured up to an additional $12 million financing with MidCap Financial. ● Placed 73 TheraClear ® X devices as of June”

STRATA Skin Sciences, Inc. amended credit facility of senior secured term loan facility of $20.0 million with MidCap Financial Trust at greater of (i) 30-day SOFR + 0.10% and (ii) 3.50% floor, plus 7.50% maturing June 1, 2028.

“The MidCap Credit Agreement provides for a senior secured term loan facility of $20.0 million”

STRATA Skin Sciences, Inc. incurred term loan of $7.0 million with MidCap Financial Trust at greater of (i) 30-day SOFR + 0.10% and (ii) 3.50% floor, plus 7.50% maturing June 1, 2028.

“Agreement (the “Amendment”) among MidCap Financial Trust (“MidCap”), as administrative agent, and the lenders identified therein, which amended the Credit and Security Agreement, dated as of September 30, 2021, as amended January 10, 2022 and”

STRATA Skin Sciences, Inc. entered into Fee Letter Agreement with MidCap Financial Trust valued at Letter agreement with MidCap as agent. (effective 2023-06-30).

“Agreement (the “Amendment”) among MidCap Financial Trust (“MidCap”), as administrative agent, and the lenders identified therein, which amended the Credit and Security Agreement, dated as of September 30, 2021, as amended January 10, 2022 and”

STRATA Skin Sciences, Inc. amended Amended and Restated Registration Rights Agreement with MidCap Funding XXVII Trust valued at Amended and restated registration rights agreement. (effective 2023-06-30).

“(c) the Amended and Restated Registration Rights Agreement (the “A&R Registration Rights Agreement”) with the Warrantholder, which amended and restated the registration rights agreement, dated as of September 30, 2021, with the Warrantholder”

STRATA Skin Sciences, Inc. amended Amended and Restated Warrant Agreement with MidCap Funding XXVII Trust valued at Amended and restated warrant agreement to purchase shares of common stock. (effective 2023-06-30).

“(b) the Amended and Restated Warrant Agreement (the “A&R Warrant”) with MidCap Funding XXVII Trust (together with any registered holder from time to time or any holder of the shares issuable or issued upon the exercise or conversion of the Warrant, the “Warrantholder”), which amended and restated the warrant agreement to purchase shares of the common stock of the Company, dated as of September 30, 2021”

STRATA Skin Sciences, Inc. amended Amendment No. 3 to Credit and Security Agreement with MidCap Financial Trust valued at Amendment to Credit and Security Agreement, providing for senior secured term loan facility of $20.0 (effective 2023-06-30).

“On June 30, 2023, STRATA Skin Sciences, Inc. (the “Company”) entered into (a) the Amendment No. 3 to Credit and Security Agreement (the “Amendment”) among MidCap Financial Trust (“MidCap”), as administrative agent, and the lenders identified therein, which amended the Credit and Security Agreement, dated as of September 30, 2021, as amended January 10, 2022 and September 6, 2022 (as amended by the Amendment, the “MidCap Credit Agreement”)”

STRATA Skin Sciences, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“June 29, 2023, STRATA Skin Sciences, Inc. (the "Company") received written notification (the "Notice") from The NASDAQ Stock Market ("NASDAQ") that the closing bid price of its common stock had been below the minimum $1.00 per share for the previous 30 consecutive business days, and that the Company is therefore not in compliance with the requirements for continued listing on the NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2). The Notice provides the Company with an initial period of 180 calendar days, or until December 26, 2023, to regain compliance with the listing rules. The C”

STRATA Skin Sciences, Inc. reported first quarter ended March 31, 2023 results: revenue $7.6 million, net income $2.8 million, EPS loss of $0.08 per basic and diluted common share. Guidance reaffirmed.

“EXHIBIT 99.1 Exhibit 99.1 Press Release dated May 15, 2023 issued by STRATA Skin Sciences, Inc. STRATA Skin Sciences Reports First Quarter 2023 Revenue Achieved revenue of $7.6 million for the first quarter 2023 Company to host conference call and webcast today, May 15, 2023, at 4:30 PM ET HORSHAM, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences,”

STRATA Skin Sciences, Inc. reported first fiscal quarter of 2023 results: revenue range of $7.3 - $7.8 million.

“--- EX-99.1 2 brhc20051325_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 STRATA Skin Sciences Pre-Announces First Quarter 2023 Results • Preliminary revenue to be within the range of $7.3 - $7.8 million and expected to be the strongest first-quarter results since first quarter of 2016 • Company exceeds plan with 44 TheraClear ® X placements in the first quarter”

STRATA Skin Sciences, Inc. reported the fiscal year ended December 31, 2022 results: revenue $36.2 million, net income Net loss for the full year 2022 was $5.5 million, or a loss of $0.16 per basic and diluted common share, EPS loss of $0.16 per basic and diluted common share. Guidance raised.

“Revenues for the full year 2022 were $36.2 million”

STRATA Skin Sciences, Inc. reported the fourth fiscal quarter and full year ended December 31, 2022 results: revenue $10.6 million, net income Net loss for the fourth quarter of 2022 was $0.2 million, or a loss of $0.005 per basic and diluted common share, EPS loss of $0.005 per basic and diluted common share. Guidance raised.

“results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Business Highlights: ● Revenue in the fourth quarter of 2022 was a record $10.6 million, an increase of 17% over the fourth quarter of 2021 ○ Global recurring revenue was $6.5 million ○ Gross domestic recurring billings were $5.8 million ● Revenue for the full year”

STRATA Skin Sciences, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“February 27, 2023 STRATA Skin Sciences, Inc. (the “Company”) received notice from The NASDAQ Stock Market (“Nasdaq”) that, STRATA has regained compliance with the Nasdaq listing requirements as required by Rule 5550(a)(2) r egarding the Company’s minimum bid price , and the Company will continue to trade on Nasdaq.”

STRATA Skin Sciences, Inc. reported the 2022 fiscal year results: revenue $35-$36 million. Guidance reaffirmed.

“2 ex_99-1.htm STRATA PRESS RELEASE DATED 2/1/2023 Exhibit 99.1 STRATA Skin Sciences Expects Record Full Year 2022 Revenue ● Unaudited, preliminary revenue within the range of $35-$36 million ● Record revenue represents approximately 17-19% growth over full year 2021 HORSHAM, Pa., February 1, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:”

STRATA Skin Sciences, Inc. reported full-year 2022 results: revenue $33 million to $35 million. Guidance reaffirmed.

“The company reiterated its full-year 2022 revenue guidance in the range of $33 million to $35 million.”

STRATA Skin Sciences, Inc. reported third quarter ended September 30, 2022 results: net income $1.0 million, EPS $0.03. Guidance reaffirmed.

“STRATA Skin Sciences Reports Strong Third Quarter 2022 Financial Results ● Strong revenue in the third quarter 2022 of $9.4 million , a 22% increase over the third quarter of 2021”

STRATA Skin Sciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 26, 2022, STRATA Skin Sciences, Inc. (the "Company") received written notification (the "Notice") from The NASDAQ Stock Market ("NASDAQ") that the closing bid price of its common stock had been below the minimum $1.00 per share for the previous 30 consecutive business days, and that the Company is therefore not in compliance with the requirements for continued listing on the NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2). The Notice provides the Company with an initial period of 180 calendar days, or until April 24, 2023, to regain compliance with the listing rules. The C”

Patricia S. Walker, M.D., Ph.D. was appointed as member of the Board of Directors at STRATA Skin Sciences, Inc..

“the Board of Directors of Strata Skin Sciences, Inc. (the “Company”) appointed Patricia S. Walker M.D., Ph.D. to serve as a member of the Company’s Board of Directors”

Douglas Strang was appointed as Chair of the Audit Committee at STRATA Skin Sciences, Inc..

“Douglas Strang, a member of the Company's Board and a member of the Audit Committee, agreed to serve as Chair of the Audit Committee effective upon Ms. Via’s resignation.”

LuAnn Via resigned as Board member, Vice Chairperson, and Chair of the Board's Audit Committee at STRATA Skin Sciences, Inc..

“LuAnn Via submitted her letter of resignation, effective December 31, 2021, from her position as a Board member, Vice Chairperson, and Chair of the Board's Audit Committee of Strata Skin Sciences, Inc.”

Douglas S. Strang was appointed as Director at STRATA Skin Sciences, Inc..

“On October 27, 2021, based upon the recommendation of the Nominating and Governance Committee, the Board of Directors of Strata Skin Sciences, Inc. (the “Company”) appointed Douglas S. Strang to serve as a member of the Company’s Board of Directors until the earlier of Mr. Strang’s resignation or his successor has been elected and qualified.”

Christopher Lesovitz was appointed as Chief Financial Officer at STRATA Skin Sciences, Inc..

“Effective October 16, 2021, the Company appointed Christopher Lesovitz (age 39) as its Chief Financial Officer.”

Matthew C. Hill resigned as Chief Financial Officer at STRATA Skin Sciences, Inc..

“On October 4, 2021, Matthew C. Hill, the Company’s Chief Financial Officer, notified the Company of his resignation effective October 15, 2021.”